Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon P Hart

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
BMC Health Services Research|November 4, 2025
The cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trialPeter May, Charles Normand, Adejoke O Oluyase, et al.
The Lancet. Respiratory Medicine|September 12, 2024
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trialIrene J Higginson, Sarah T Brown, Adejoke O Oluyase, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 30, 2017
British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency DisordersJohn R Hurst, Nisha Verma, David Lowe, et al.
ERJ Open Research|October 1, 2025
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Tamara Hernandez-Beeftink, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Amy D Stockwell, et al.
The Lancet. Respiratory Medicine|October 26, 2017
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association studyRichard J Allen, Joanne Porte, Rebecca Braybrooke, et al.
ERJ Open Research|February 20, 2024
Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosisBeatriz Guillen-Guio, Megan L Paynton, Richard J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2023
Association study of human leukocyte antigen (HLA) variants and idiopathic pulmonary fibrosisBeatriz Guillen-Guio, Megan L Paynton, Richard J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasetsDaniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, et al.
The European Respiratory Journal|May 21, 2026
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasetsDaniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
BMC Health Services Research|November 4, 2025
The cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trialPeter May, Charles Normand, Adejoke O Oluyase, et al.
The Lancet. Respiratory Medicine|September 12, 2024
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trialIrene J Higginson, Sarah T Brown, Adejoke O Oluyase, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 30, 2017
British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency DisordersJohn R Hurst, Nisha Verma, David Lowe, et al.
ERJ Open Research|October 1, 2025
Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Tamara Hernandez-Beeftink, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Genome-wide SNP-sex interaction analysis of susceptibility to idiopathic pulmonary fibrosisOlivia C Leavy, Anne F Goemans, Amy D Stockwell, et al.
The Lancet. Respiratory Medicine|October 26, 2017
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association studyRichard J Allen, Joanne Porte, Rebecca Braybrooke, et al.
ERJ Open Research|February 20, 2024
Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosisBeatriz Guillen-Guio, Megan L Paynton, Richard J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2023
Association study of human leukocyte antigen (HLA) variants and idiopathic pulmonary fibrosisBeatriz Guillen-Guio, Megan L Paynton, Richard J Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasetsDaniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, et al.
The European Respiratory Journal|May 21, 2026
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasetsDaniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, et al.
Pageof 11